A Phase 1, First Time in Humans Study of NST-1024

Inclusion Criteria: * BMI 18-32 kg/m2 * In good health * Females will not be pregnant or lactating. Females of childbearing potential must agree to use contraception * Male subjects must agree to use contraception and refrain from donation of sperm * Able to comprehend and willing to sign an ICF and to abide by the study restrictions. * Subjects must have TG levels \> 150 mg/dL at screening (Part B only). Exclusion Criteria: * Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, CV, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee). * History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection. * History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed). * Aspartate aminotransferase, ALT, GGT, ALP, or total bilirubin \> 1.2 × ULN at Screening or (first) Check-in, confirmed by 1 repeat if necessary * History of alcoholism or drug/chemical abuse within 2 years prior to Check-in. * Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days or 5 half-lives (whichever is longer) prior to dosing. * Use of tobacco- or nicotine-containing products within 1 month prior to Screening, or positive cotinine test at Screening or Check-in.